Copyright
©The Author(s) 2022.
World J Gastroenterol. Mar 7, 2022; 28(9): 961-972
Published online Mar 7, 2022. doi: 10.3748/wjg.v28.i9.961
Published online Mar 7, 2022. doi: 10.3748/wjg.v28.i9.961
Table 1 Patients’ characteristics according to clinical remission status
Clinical remission, n (%) unless otherwise specified | ||
No, n = 19 | Yes, n = 15 | |
Female sex | 10 (53%) | 6 (40%) |
Age (yrs), Med [IQR] | 34 [27-38] | 35 [23-44] |
BMI, Med [IQR] | 28 [19-32] | 22 [20-23] |
Number of comorbidities1, Med [IQR] | 0 [0-1] | 0 [0-1] |
Active smoking, 1 MD | 9 (47%) | 6 (43%) |
Crohn’s disease phenotype (Montreal L) | ||
Terminal ileum | 3 (16%) | 4 (27%) |
Colon | 8 (42%) | 5 (33%) |
Ileo-colon | 8 (42%) | 5 (33%) |
Upper digestive tract | 0 (0%) | 1 (7%) |
Crohn’s disease phenotype (Montreal B) | ||
Non-stricturing, non-penetrating | 12 (63%) | 8 (53%) |
Stricturing | 4 (21%) | 2 (13%) |
Penetrating | 2 (11%) | 2 (13%) |
Stricturing + penetrating | 1 (5%) | 3 (20%) |
Number of fistulas, Med [IQR] | 2 [1-2] | 2 [1-2] |
Complex fistula | 17 (89%) | 11 (73%) |
Vaginal fistula | 4 (21%) | 1 (7%) |
Previous treatment with infliximab | 10 (53%) | 7 (47%) |
Previous treatment with another anti-TNF-α2 | 10 (53%) | 7 (47%) |
Previous treatment with another form of biotherapy3 | 10 (53%) | 7 (47%) |
Previous treatment with combination therapy | 12 (63%) | 5 (33%) |
Previous abdominal surgery | ||
No | 14 (74%) | 11 (73%) |
Appendicectomy | 0 (0%) | 2 (13%) |
Ileocecal resection | 4 (21%) | 2 (13%) |
Colectomy | 1 (6%) | 0 (0%) |
Previous fistulotomy | 4 (21%) | 6 (40%) |
Previous seton | 18 (95%) | 13 (87%) |
Previous flattening of abscesses | 8 (42%) | 10 (67%) |
Previous closure techniques | 3 (16%) | 5 (33%) |
Previous glue | 2 (11%) | 4 (27%) |
Previous plug | 0 (0%) | 1 (7%) |
Previous rectal advancement flap | 1 (5%) | 0 (0%) |
Optimization at first visit | 8 (42%) | 9 (60%) |
Combination therapy (with methotrexate or thiopurine) at first visit | 12 (63%) | 5 (33%) |
Combination therapy and/or optimization at first evaluation | 15 (79%) | 9 (60%) |
- Citation: Sirmai L, Pelletier AL, Gault N, Zallot C, Bouguen G, Bouchard D, Roland Nicaise P, Peyneau M, Sironneau S, Bittencourt MDC, Petitcollin A, Fernandez P, Roblin X, Siproudhis L, Abramowitz L. Relationship between clinical remission of perianal fistulas in Crohn’s disease and serum adalimumab concentrations: A multi-center cross-sectional study. World J Gastroenterol 2022; 28(9): 961-972
- URL: https://www.wjgnet.com/1007-9327/full/v28/i9/961.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i9.961